BMS-378806, also known as BMS378806 and CAS number 357263-13-9, is a selective antagonist of the dopamine D3 receptor. This product has gained attention in recent years due to its potential therapeutic benefits in the treatment of various psychiatric disorders such as depression, addiction, and schizophrenia.
Chemical name: The chemical name of BMS-378806 is (R)-3-(4-(2-(6,7-dihydro-1-methyl-5H-benzo[d]azepin-5-yl)ethyl)piperazin-1-yl)-5-(trifluoromethyl)pyridine.
Molecular formula: The molecular formula of BMS-378806 is C24H26F3N4.
Formula weight: The formula weight of BMS-378806 is 438.49 g/mol.
CAS No: The CAS number of BMS-378806 is 357263-13-9.
Top ten keywords from Google and Synonyms:
Synonyms for BMS-378806 include (R)-3-(4-(2-(6,7-dihydro-1-methyl-5H-benzo[d]azepin-5-yl)ethyl)piperazin-1-yl)-5-(trifluoromethyl)pyridine, BMS-378806, and 357263-13-9.
Health benefits of this product: BMS-378806 has the potential to provide numerous health benefits in the treatment of various psychiatric disorders. As an antagonist of the dopamine D3 receptor, it can help regulate the levels of this neurotransmitter in the brain, which has been linked to mood disorders such as depression and addiction. Additionally, studies have shown that BMS-378806 may be effective in reducing symptoms of schizophrenia by blocking the overactivity of dopamine in certain areas of the brain.
Potential effects: The potential effects of BMS-378806 are vast and varied. Its selectivity as a dopamine D3 receptor antagonist means that it can target specific areas of the brain associated with psychiatric disorders, providing greater efficacy and fewer side effects than non-selective treatments. Additionally, its ability to regulate dopamine levels can help balance mood and reduce the risk of substance abuse.
Product mechanism: BMS-378806 works by inhibiting the binding of dopamine to the D3 receptor. This receptor is primarily found in the mesolimbic pathway of the brain, which is responsible for regulating pleasure, motivation, and reward. By blocking the activation of this receptor, BMS-378806 can reduce the release of dopamine in this area, which has been linked to the development of addiction and other psychiatric disorders.
Safety: While BMS-378806 has shown significant promise in preclinical studies, its safety profile in humans remains unknown. As with any new medication, it will need to undergo extensive clinical trials to confirm its efficacy and safety before it can be approved for use. It is essential to consult a healthcare professional before starting any new medication or treatment regimen.
Side effects: As a new medication, the potential side effects of BMS-378806 are not yet fully understood. However, based on preclinical studies, it appears to have a favorable side effect profile compared to non-selective dopamine antagonists. Nevertheless, some potential side effects include dizziness, nausea, headache, and gastrointestinal distress.
Dosing information: As BMS-378806 is still in the preclinical phase of development, dosing information is not yet available. However, it is likely that dosages will vary depending on the severity of the condition being treated, the patient's age, weight, and other factors. It is crucial to follow the advice of a healthcare professional when taking any medication.
Conclusion: In conclusion, BMS-378806 shows significant potential in treating various psychiatric disorders such as depression, addiction, and schizophrenia. As a selective antagonist of the dopamine D3 receptor, it provides greater efficacy and fewer side effects than non-selective treatments. However, more research is needed to confirm its efficacy and safety before it can be approved for use. It is essential to consult a healthcare professional before starting any new medication or treatment regimen
